Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HutchMed to Raise $600 Million in Hong Kong IPO

publication date: Jun 18, 2021

Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong Kong IPO. HutchMed has launched two novel oncology drugs in China, and it has eight more candidates in development. The Hong Kong IPO is the third listing for the company, following its first on London's AIM exchange and then NASDAQ in the US. The company has a $4.3 billion market cap on NASDAQ. Cornerstone investors have agreed to purchase $325 million (54%) of the offered shares. HutchMed will set the purchase price on June 23. More details....

Stock Symbols: (NSDQ/AIM: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.